deltatrials
Completed PHASE1 INTERVENTIONAL 1-arm NCT01388335

A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin

The Effect of Enzastaurin on CYP2C9: Enzastaurin - S-Warfarin Drug Interaction Study in Patients With Cancer

Sponsor: Eli Lilly and Company

Conditions Lymphoma, Malignant Solid Tumor
Interventions enzastaurin warfarin
Updated 8 times since 2017 Last updated: Jun 9, 2020 Started: Aug 31, 2011 Primary completion: Oct 31, 2012 Completion: Dec 31, 2012
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Lymphoma, Malignant and Solid Tumor, this trial is completed. The trial is conducted by Eli Lilly and Company and has accumulated 8 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Aug 2020 · 26 months · monthly snapshotCompleted~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotCompleted~Sep 2025 – present · 10 months · monthly snapshotCompleted

Change History

8 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  5. Aug 2020 — Jan 2021 [monthly]

    Completed PHASE1

▶ Show 3 earlier versions

  1. Jun 2018 — Aug 2020 [monthly]

    Completed PHASE1

  2. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1

    First recorded

Aug 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eli Lilly and Company
Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations